

## **Description of Additional Supplementary Files:**

**Supplementary Data 1:** Construction of all plasmids generated in this study. Plasmids have been generated by restriction-ligation cloning or Gibson Assembly using templates and oligonucleotides as listed in this table. Additional information about procedures is available in the Methods section.

**Supplementary Data 2:** Clinical *Pseudomonas aeruginosa* strains used in this study. This table lists clinical isolates of *P. aeruginosa* that were tested for Paride sensitivity and their drug resistances (if known). Based on these results, the strains used in Fig. 3A,B have been selected.